MariMed Showcasing Cannabis Opportunity at Investment Conferences
- Opal Family Office Winter Forum – New York City, March 6, 2019
- Roth Conference – Laguna Niguel, CA, March 18-19
NORWOOD, MA, March 05, 2019 (GLOBE NEWSWIRE) -- MariMed Inc. (OTCQB: MRMD) a multi-state cannabis operator and hemp CBD product producer, announced today that it will be appearing at two investment conferences in March.
On Wednesday, March 6, MariMed senior management will attend the Opal Group’s Family Office Winter Forum held at the Marriott Marquis Hotel in Times Square, New York City. It is one of the largest family office events in the U.S. Additionally, MariMed CEO Bob Fireman will participate in a 4:00 PM panel discussion focusing on investing in the cannabis industry.
March 18-19, MariMed senior management will be at the 31st Annual Roth Conference at The Ritz Carlton, Laguna Niguel in Orange County, Calif. This conference is expected to attract close to 550 participating companies and over 4,700 attendees, and will feature presentations from public and private companies in a variety of sectors.
MariMed CEO Bob Fireman noted, “Since the passage of the 2018 Farm Bill, health and wellness products containing hemp-derived CBD are legal nationally. As one of the largest multi-state cannabis operators in the U.S., and as an early investor in high quality, hemp-derived CBD production, we are uniquely well positioned for future growth. MariMed management looks forward to contributing to the investment community’s understanding of this industry and its potential to improve health and wellness across a broad spectrum of conditions.”
About MariMed Inc.
MariMed, Inc. is dedicated to improving health and wellness with the highest quality hemp and cannabis products. The company distributes a full range of branded cannabis products in select states, operates state of the art cannabis facilities in multiple states, and has recently announced the formation of a separate division, MariMed Hemp, focused on the development of industrial hemp-derived CBD products. In late 2018, the Company announced a $30MM investment in Kentucky-based GenCanna, a recognized genetic innovator in industrial hemp. Across its branded products, MariMed is on the forefront of precision dosed branded products for the treatment of specific medical symptoms. MariMed is expanding licensing and distribution to numerous additional markets encompassing thousands of dispensaries.
For additional information, visit www.MariMedAdvisors.com.
Search MariMed and post on social media with the hash tag #MedicatedByMarimed:
Twitter: @MariMedInc Facebook: @MariMedInc Instagram: MariMedInc YouTube: MariMedInc
Forward Looking Statements:
This release contains certain forward-looking statements and information relating to MariMed Inc. that is based on the beliefs of MariMed Inc.’s management, as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events including estimates and projections about its business based on certain assumptions of its management, including those described in this Release. These statements are not guarantees of future performance and involve risk and uncertainties that are difficult to predict, including, among other factors, changes in demand for the Company's services and products, changes in the law and its enforcement and changes in the economic environment. Additional risk factors are included in the Company's public filings with the SEC. Should one or more of these underlying assumptions prove incorrect, actual results may vary materially from those described herein as "hoped," "anticipated," "believed," "planned, "estimated," "preparing," "potential," "expected," “looks” or words of a similar nature. The Company does not intend to update these forward-looking statements. None of the content of any of the websites referred to herein (even if a link is provided for your convenience) is incorporated into this release and the Company assumes no responsibility for any of such content.
Media: Julie Shepherd, Accentuate PR
Investors: Jon Levine, CFO, MariMed
Released March 5, 2019